Methyl (E)-N-benzylideneglycinate | 66646-88-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl (E)-N-benzylideneglycinate
• 英文别名: methyl 2-(benzylideneamino)acetate；(E)-N-benzylideneglycine methyl ester；(benzylidene-amino)-acetic acid methyl ester；(E)-2-((benzylidene)amino)acetic acid methyl ester；(E)-(benzylidene-amino)-acetic acid methyl ester；(E)-N-phenylmethyleneglycine methyl ester；methyl (E)-N-(phenylmethylene)glycinate；(E)-methyl 2-(benzylideneamino)acetate
• CAS: 66646-88-6；120238-40-6；138495-05-3
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: YOIONBBMZSLNLR-YRNVUSSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  13.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  38.66
• 氢给体数：
  0.0
• 氢受体数：
  3.0

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2925290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  Methyl (E)-N-benzylideneglycinate 在 Taniaphos potassium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 8.0h， 生成 (2R,4S,5R)-methyl 1-methyl-5-phenyl-4-(phenylsulfonyl)pyrrolidine-2-carboxylate
  参考文献：
  名称：

  铜(I)催化偶氮甲碱叶立德与乙烯基砜的对映选择性1,3-偶极环加成

  摘要：

  铜 (I)-Taniaphos (5 mol%) 的组合是一种有效的路易斯酸催化剂，可促进偶氮甲碱叶立德与芳基乙烯基砜的不对称 1,3-偶极环加成，以良好的收率和几乎完全的外选择性和良好的对映控制（通常为 65-85% ee）。在简单的重结晶、N-甲基化和随后的还原脱磺酰化之后，环加合物转化为高对映纯度（>99% ee）的顺式-2,5-二取代吡咯烷已完成。

  DOI：

  10.1055/s-2007-965926
• 作为产物：
  描述：

  10-O-tert-butyl 1-O-methyl 2-(benzylideneamino)decanedioate 在 柠檬酸 作用下， 以 乙醚 为溶剂， 反应 48.0h， 生成 Methyl (E)-N-benzylideneglycinate
  参考文献：
  名称：

  Structure-Based Design of New Constrained Cyclic Agonists of the Cholecystokinin CCK-B Receptor

  摘要：

  New constrained cyclic pseudopeptide cholecystokinin-B (CCK-B) agonists have been designed on the basis of conformational characteristics of the potent and selective CCK-B agonist Boc-Trp-(NMe)Nle-Asp-Phe-NH2 (K-i = 0.8 nm, selectivity ratio CCK-A/CCK-B > 6000) (Goudreau et al. Biopolymers, 1994, 34, 155-169). These compounds are among the first successful examples of macrocyclic constrained CCK4 analogs endowed with agonist properties and as such may be of value for the development of nonpeptide CCK-B agonists. The affinities and selectivities of these compounds for CCK-B and CCK-A receptors have been determined in vitro by measuring the displacement of [H-3]pCCK(8) binding to guinea pig cortex and pancreas membranes, respectively. The most potent compound, 8b, N-(cycloamido)-alpha-Me(R)Trp-[(2S)-2-amino-9-((cycloamido)carbonyl)nonanoyl]-Asp-Phe-NH2, has a K-i value of 15 +/- 1 nM for guinea pig cortex membranes with a good CCK-B selectivity ratio (CCK-A/CCK-B = 147). Furthermore, 8b behaved as a potent and full agonist in a functional assay which measures the stimulation of inositol phosphate accumulation in CHO cells transfected with the rat CCK-B receptor (EC(50) = 7 nM). The in vivo affinity of 8b for mouse brain CCK-B receptors was determined following intracerebroventricular injection (ID50 similar to 29 nmol/kg). 8b was also shown to cross the blood-brain barrier (0.16%), after intravenous administration in mice. 8b also increased gastric acid secretion measured in anesthetized rats after intravenous injection. Therefore, 8b appears to be an interesting pharmacological tool and is currently under investigation as a lead for further development of nonpeptide CCK-B agonists.

  DOI：

  10.1021/jm9603072

文献信息

• [EN] AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE<br/>[FR] DÉRIVÉS D'AMINOQUINAZOLINE ET LEURS SELS ET PROCÉDÉS D'UTILISATION
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2013071697A1

  公开（公告）日：2013-05-23

  The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

  本发明涉及医学领域。本文提供了氨基喹唑啉衍生物、其盐和药物配方，用于调节蛋白酪氨酸激酶活性，以及调节细胞间和/或细胞内信号传导。本文还提供了包含氨基喹唑啉化合物的药用可接受组合物，以及使用这些组合物治疗哺乳动物，特别是人类的增生性疾病的方法。
• AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20140228361A1

  公开（公告）日：2014-08-14

  The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

  本发明涉及医学领域。本文提供了氨基喹唑啉衍生物，其盐和药物配方在调节蛋白酪氨酸激酶活性以及调节细胞间和/或细胞内信号传导方面具有用处。本文还提供了包含氨基喹唑啉化合物的药用可接受组合物，以及在治疗哺乳动物，特别是人类的增生性疾病中使用这些组合物的方法。
• Substituted Pyrrolidines and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20180099931A1

  公开（公告）日：2018-04-12

  The invention discloses compounds of Formula (I) wherein R 1 , R 2 , R 2A , R 3 , R 3A , R 4 , R 4A , and R 5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  该发明公开了式（I）的化合物 其中R 1 ，R 2 ，R 2A ，R 3 ，R 3A ，R 4 ，R 4A 和R 5 如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予该发明的化合物来治疗囊性纤维化的方法。
• X=Y-ZH systems as potential 1.3-dipoles
  作者：Ronald Grigg、H.Q.Nimal Gunaratne、Visuvanathar Sridharan

  DOI：10.1016/s0040-4020(01)87794-2

  日期：——

  Cycloadditions of arylidene imines of α-amino acid esters to a range of dipolarophiles show substantial rate enhancements in the presence of Bronsted and Lewis acids. For Bronsted acids the rate is related to the pKa of the acid and cycloadditions to reactive dipolarophiles occur at room temperature. For the Lewis acids studied the rate acceleration decreases in the order Zn(OAc)2 > AgOAc > LiOAc >

  在布朗斯台德和路易斯酸的存在下，α-氨基酸酯的亚芳基亚胺与一系列偶极亲和剂的环加成反应显示出显着的速率增加。对于布朗斯台德酸，速率与该酸的pK a有关，并且在室温下发生向反应性双极性亲和剂的环加成。对于所研究的路易斯酸，速率加速以Zn（OAc）2 > AgOAc> LiOAc> MgOAc 2的顺序降低，但也依赖于LiBr> LiOAc和AgOAc> AgOTs的阴离子。据信路易斯酸催化的方法是金属-1，3-偶极的环加成的实例。在布朗斯台德和路易斯酸催化过程中，环加成都是区域和立体特异性的。
• The absolute configuration and total synthesis of korormicin
  作者：Hisatoshi Uehara、Tohru Oishi、Kazuhiro Yoshikawa、Kenichi Mochida、Masahiro Hirama

  DOI：10.1016/s0040-4039(99)01812-2

  日期：1999.12

  The marine antibiotic korormicin, isolated from the culture filtrate of marine bacterial strain Pseudoalteromonas sp. F-420, specifically inhibits the growth of marine Gram-negative bacteria without affecting terrestrial species. The absolute configuration of korormicin was determined by the combination of a CD exciton chirality method and chemical degradation. Convergent total synthesis of koromicin

  从海洋细菌菌株Pseudoalteromonas sp。的培养滤液中分离出的海洋抗生素科洛美霉素。F-420特异性抑制海洋革兰氏阴性细菌的生长，而不会影响陆地物种。通过CD激子手性法和化学降解的组合来确定科霉素的绝对构型。还已经实现了koromicin的聚合全合成。